Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Atul Verma, MD, director of cardiology at McGill University Health Centre in Montreal, explained why the late-breaking PULSED-AF trial data on Medtronic’s pulsed-field ablation technology is so important for cardiologists.
A new experimental study focused on how different sex hormones can affect the heart's ability to properly pump blood. Estradiol, the most active form of estrogen, stood out as a hormone that requires additional research.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
